Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TAA-05 by PersonGen BioTherapeutics (Suzhou) for Refractory Acute Myeloid Leukemia: Likelihood of Approval
TAA-05 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase II for Refractory Acute Myeloid Leukemia. According...
Data Insights
TAA-05 by PersonGen BioTherapeutics (Suzhou) for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
TAA-05 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase II for Relapsed Acute Myeloid Leukemia. According...